Efficacy and Safety of Rituximab, High-dose Ara-C and Dexamethasone (R-HAD) Alone or in Combination With Bortezomib in Patients With Relapsed or Refractory Mantle Cell Lymphoma.

Trial Profile

Efficacy and Safety of Rituximab, High-dose Ara-C and Dexamethasone (R-HAD) Alone or in Combination With Bortezomib in Patients With Relapsed or Refractory Mantle Cell Lymphoma.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 24 Jul 2017

At a glance

  • Drugs Bortezomib (Primary) ; Cytarabine; Dexamethasone; Rituximab
  • Indications Mantle-cell lymphoma; Non-Hodgkin's lymphoma
  • Focus Therapeutic Use
  • Acronyms R-HAD
  • Most Recent Events

    • 24 Jul 2017 This trial has been suspended in Germany as per European Clinical Trials Database.
    • 06 Mar 2017 Planned End Date changed from 1 Sep 2016 to 1 Dec 2018.
    • 06 Mar 2017 Planned primary completion date changed from 1 Sep 2016 to 1 Dec 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top